Michael Heffernan - Concepedia

Author

Michael Heffernan

Also Known As

C Mcatee, Daniel Hedequist, Heffernan, M.; Quinn, J.; Tschautscher, C.; Newberry, R.; Cathers, A.; Bernardoni, B., Karen Boyd, M Heffernan, M. Heffernan, M.P. Heffernan, MICHAEL HEFFERNAN, MP Heffernan, Michael C. Giudici

124

Publications

6.8K

Citations

H-Index

Concepts

All Affiliations

University of Toronto Southlake Regional Health Center Wright State University McMaster University Canadian Heart Research Centre

About

Michael Heffernan is an author at University of Toronto specializing in medicine, dermatology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	4K
2	Health Sciences	1	1	52
3	Language Studies	1	1	15
4	Public Health	1	1	20
5	Diabetes	1	1	52

Michael Heffernan

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Sonia S. Anand, Jackie Bosch, John W. Eikelboom, The Lancet ThrombosisCardiovascular DiseaseStrokeMedicinePlacebo-controlled Trial	2017	855
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, The Lancet Randomised TrialsClinical TrialsClinical DermatologyDermatologyExperimental Dermatology	2015	815
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Stuart J. Connolly, John W. Eikelboom, Jackie Bosch, The Lancet ThrombosisCardiovascular DiseaseAtherosclerosisMedicineCoronary Artery Disease	2017	749
Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction Warren J. Cantor, David Fitchett, Bjug Borgundvaag, New England Journal of Medicine	2009	578
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study Kenneth B. Gordon, Richard G. Langley, Craig L. Leonardi, Journal of the American Academy of Dermatology Open-label Extension StudySystemic TreatmentSevere PsoriasisClinical TrialsTreatment Option	2006	502
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis Cynthia Helms, Li Cao, James G. Krueger, Nature Genetics MedicineImmunologyClinical DermatologyDermatologyPsoriatic Arthritis	2003	302
Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure Harriette G.C. Van Spall, Shun Fu Lee, Feng Xie, JAMA	2019	251
Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial Craig A. Elmets, Jaye L. Viner, Alice P. Pentland, JNCI Journal of the National Cancer Institute	2010	240
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens, Journal of the American Heart Association	2016	196
Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii, Journal of the European Academy of Dermatology and Venereology	2014	130

Page 1